United Therapeutics Corp. (NASDAQ: UTHR) suffered from the announcement of the results of the FREEDOM-M Study on June 6, 2011, and FREEDOM-C^2 Study on August 24, 2011, respectively, which eventually resulted in the stock plummeting to a one-year low of 38.87 per share on August 24, 2011 . Prior to making these announcements, Company insiders made encouraging statements regarding the studies while contrarily executing numerous lucrative trades in UTHR stock in the weeks and months preceding. United Therapeutics Corp said its experimental oral lung drug failed to meet the main goal of improving walking ability of patients with pulmonary arterial hypertension in a late-stage trial. The company's stock was trading down 16 percent at $40.80 on 8/31/11. It fell to $38.87 earlier in the session -- the stock's lowest in more than two-years. The trial, named FREEDOM-C(2), was testing an oral formulation of treprostinil in patients with pulmonary arterial hypertension (PAH), and adds to the disappointment from another late-stage study that improved walking ability but was low on efficacy. Treprostinil is already approved to treat PAH patients by subcutaneous, intravenous and inhaled routes of administration, and the company expects data from other late-stage trials to support an approval for the oral version. The main goal of the trial, which had 310 patients, was to show statistically significant improvement in patients' six-minute walk distance -- a standard test to assess lung capacity -- at the 16th week of treatment. Oral versions of drugs are usually pegged as big sellers given the ease of administration. Meacham had estimated the drug to earn $50 million in 2013 and $235 million in 2015. Pulmonary hypertension is a chronic, life-threatening illness, and sufferers experience shortness of breath during physical activities such as walking and exercising. Patients on the latest trial received an already-approved oral therapy and either the oral drug or a placebo. Percentage of patients dropping off the trial or discontinuing due to adverse events was also higher in the oral treprostinil arm -- 11 percent compared with 3 percent in the placebo arm. Adverse events included headache, nausea and vomiting. Prostacyclin is the active ingredient of the drug. The injectible version of treprostinil is marketed as Remodulin, and the inhaled version is marketed as Tyvaso. The Silver Spring, Maryland-based company had $555.4 million in combined sales from Remodulin and Tyvaso, nearly 92 percent of its total revenue. Its other marketed drug is Adcirca, which contributed 6 percent of the revenue.

If you are a current shareholder and purchased your shares prior to August 24, 2011, and would like to discuss your options of exercising your rights as a shareholder, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.